What are the anticipated acquisition benefits of the transaction?
The acquisition of BioFX by SurModics: –Helps drive many elements of SurModics’ strategic growth plan, including revenue diversification –Broadens SurModics’ product portfolio within the in vitro Diagnostics market –Provides complementary customer bases between the two companies –Diversifies SurModics’ revenue streams –Is expected to be accretive in fiscal 2008